Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Bevacizumab + Carboplatin + Paclitaxel |
Indication/Tumor Type | fallopian tube cancer |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | fallopian tube cancer | not applicable | Bevacizumab + Carboplatin + Paclitaxel | FDA approved | Actionable | In a Phase III trial (GOG-0218) that supported FDA approval, addition of Avastin (bevacizumab) during and after Paraplatin (carboplatin) plus Taxol (paclitaxel) treatment prolonged progression-free survival (14.1 vs 10.3 months) compared to placebo in patients with previously untreated, stage III/IV epithelial ovarian, primary peritoneal, or fallopian tube cancer (PMID: 22204724; NCT00262847). | detail... 22204724 |
PubMed Id | Reference Title | Details |
---|---|---|
(22204724) | Incorporation of bevacizumab in the primary treatment of ovarian cancer. | Full reference... |
Avastin (bevacizumab) FDA Drug Label | Full reference... |